Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 15/20 | 0.55 |
| ▸ | MET | P08581 | 13/20 | 0.55 |
| ▸ | MERTK | Q12866 | 3/20 | 0.48 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.45 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.45 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18044588 | 0.87 | AXL (0.59) | AXLMETMERTKFLT3TYRO3 | |
| SCHEMBL16709405 | 0.85 | AXL (0.57) | AXLMETMERTKFLT3TYRO3 | |
| SCHEMBL18044611 | 0.85 | AXL (0.57) | AXLMETMERTKFLT3KDR | |
| SCHEMBL16709459 | 0.85 | AXL (0.59) | AXLMETMERTKFLT3IKBKE | |
| SCHEMBL20344602 | 0.85 | AXL (0.57) | AXLMETMERTKFLT3TYRO3 | |
| SCHEMBL18045151 | 0.83 | AXL (0.55) | AXLMETMERTKFLT3TYRO3 | |
| Trifluoroacetic Acid SCHEMBL18044744 | 0.83 | AXL (0.57) | AXLMETMERTKFLT3IKBKE | |
| SCHEMBL18044640 | 0.82 | AXL (0.54) | AXLMETMERTKFLT3TYRO3 | |
| SCHEMBL20344713 | 0.82 | AXL (0.56) | AXLMETMERTKFLT3KDR | |
| SCHEMBL18045193 | 0.81 | AXL (0.53) | AXLMETMERTKFLT3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3067356-B1 | PYRROLO PYRIMIDINE DERIVATIVE | ONO PHARMACEUTICAL CO (JP) | 2018-07-04 | — | — | EP | disclosed |
| US-9586967-B2 | Pyrrolo pyrimidine derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-03-07 | — | — | US | disclosed |
| US-20160264579-A1 | PYRROLO PYRIMIDINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-09-15 | — | — | US | disclosed |
| EP-3067356-A1 | PYRROLO PYRIMIDINE DERIVATIVE | ONO Pharmaceutical Co., Ltd. (JP) | 2016-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264579-A1 | PYRROLO PYRIMIDINE DERIVATIVE | AXL, FLT3, TYRO3 | AXL 1/4885MET 398/4885MERTK 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.